HCW Biologics Inc. HCWB
HCW Biologics Inc. (Nasdaq: HCWB) is an immunology/inflammation drug developer. Its lead program, HCW9302, is in Phase 1 for Alopecia areata (autoimmune). Its next catalyst on record is HCW9302: Full Phase 1 human data readout (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: HCW9302 — Full Phase 1 human data readout (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| HCW9302 | Alopecia areata (first-in-human, dose escalation) | protein/peptide | Phase 1 |
| HCW11-018b | Solid tumors (tetravalent T-cell engager) | antibody | Pre-clinical |
| HCW11-040 | Bronchopulmonary dysplasia (cytokine/PD-1 fusion) | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.